While cancer immunotherapies are definitely becoming more de rigeur these days, that doesn’t mean that good old fashioned targeted therapies have been universally abandoned or forgotten, far from it.
Making strategic choices about how to differentiate targeted therapies is never easy
At recent meetings this year, my attention was caught by one target in particular, and despite its chequered history it seems to be making a comeback of sorts thanks to a more focused and tailored approach to therapy.
There is unlikely to be one panacea for everything, but what about going back to basics and matching patients to appropriate therapy based on the underlying biology and what the patiemt’s tumour is telling us? We should have more success doing that theoretically – is that actually the case in practice?
To illustrate this, we have a few examples to share from one particular niche in oncology that readers may find interesting and useful…
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
The hurly burly in Chicago between sessions
We have written about the positive and negative effects of various inhibitory checkpoints such as PD-L1, PD-L2, ICOS, and even B7-H3, but there are also other targets within the B7 family that might be worthwhile exploring in the clinic.
Beyond the hullabaloo surrounding the phase 3 anti-PD(L)1 data in 1L NSCLC, there were actually a lot of interesting new and emerging molecules that caught our attention from small biotechs that we plan to highlight throughout the rest of this week. They all have different targets, approaches and rationales, but offer a window into the world of oncology R&D and where things might be headed in the next couple of years.
Today we take a look at one of the long forgotten checkpoint targets and explore a number of aspects that can be considered, given that several companies have preclinical or clinical molecules in early development.
Is this an IO target to watch out for – or not? What are the challenges and opportunities to consider?
It turns out that there could be more than one way to unleash T cells on cancer… as this interview with a company scientist and researcher demonstrates.
To learn more and get a heads up on our latest thought leader interviews and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Sometimes initial phase 1/1b readouts at cancer conferences produce quite different reactions from a live and remote audience while at other meetings, the Developmental Therapeutics talks produce little or no interest at all. It’s often hard to guage which way they will go.
At SITC this weekend, several talks generated some contentious, and at times quite heated, debate and intense interest.
One of these was an oral presentation by Dr Zev Wainberg on the first-in-man data with the anti-CSF1R and anti-PD1 inhibitors, cabiralizumab and nivolumab, from Five Prime and BMS respectively, in an advanced pancreatic cohort.
Dr Zev Wainberg at SITC 2017
There was a surprising amount of confusion surrounding the initial results and other issues last week, with Five Prime’s stock dropping before we’d even got to Dr Wainberg’s talk.
What became increasingly obvious over the weekend was a clear difference in investors perceptions versus what the scientific community actually thought.
Here we take a look at the data and explain what to watch out for and why…
To learn more insights on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
We’ve been saying for a while that 2017 and onwards would be when we start to see a few IO combination trials start to shake out. Interestingly, that process seems to have already started, if recent news is any thing to go by.
With this in mind, the annual meeting of the American Association for Cancer Research (AACR) coming up this weekend gives us a timely moment to explore combinations that are looking interesting… or not.
In the last of our AACR 2017 Conference Previews, we take a look at what to expect on this year’s program in the IO and Checkpoint arena. In short, it’s quite a lot and not without some controversy either!
Subscribers can log-in to learn more…